Walsuralactam ACAS# 1370556-82-3 |
2D Structure
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
Cas No. | 1370556-82-3 | SDF | Download SDF |
PubChem ID | 125181893 | Appearance | Powder |
Formula | C26H31NO5 | M.Wt | 437.53 |
Type of Compound | Triterpenoids | Storage | Desiccate at -20°C |
Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
SMILES | CC1(C(=O)C=CC2(C1=C(C(=O)C3(C2CCC4(C35C(O5)CC4C6=CCNC6=O)C)C)O)C)C | ||
Standard InChIKey | YEYOJXZXQUDNJO-OTCYVHTESA-N | ||
Standard InChI | InChI=1S/C26H31NO5/c1-22(2)16(28)7-9-23(3)15-6-10-24(4)14(13-8-11-27-21(13)31)12-17-26(24,32-17)25(15,5)20(30)18(29)19(22)23/h7-9,14-15,17,29H,6,10-12H2,1-5H3,(H,27,31)/t14-,15+,17+,23+,24-,25-,26+/m0/s1 | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | 1. Walsuralactam A in the formula I, which is used as an active ingredient, and is used for treating and preventing the tumour. |
Walsuralactam A Dilution Calculator
Walsuralactam A Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 2.2856 mL | 11.4278 mL | 22.8556 mL | 45.7112 mL | 57.1389 mL |
5 mM | 0.4571 mL | 2.2856 mL | 4.5711 mL | 9.1422 mL | 11.4278 mL |
10 mM | 0.2286 mL | 1.1428 mL | 2.2856 mL | 4.5711 mL | 5.7139 mL |
50 mM | 0.0457 mL | 0.2286 mL | 0.4571 mL | 0.9142 mL | 1.1428 mL |
100 mM | 0.0229 mL | 0.1143 mL | 0.2286 mL | 0.4571 mL | 0.5714 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Episyringaresinol 4'-O-β-D-glncopyranoside
Catalog No.:BCC8957
CAS No.:137038-13-2
- Pseudoginsenoside Rh2
Catalog No.:BCC8353
CAS No.:1370264-16-6
- PRT062607 Hydrochloride
Catalog No.:BCC1869
CAS No.:1370261-97-4
- 3',4'-Di-O-acetyl-2',6'-di-O-p-coumaroylastragalin
Catalog No.:BCN6610
CAS No.:137018-33-8
- Amprolium HCl
Catalog No.:BCC4626
CAS No.:137-88-2
- L-Ascorbyl 6-palmitate
Catalog No.:BCC4915
CAS No.:137-66-6
- Lidocaine
Catalog No.:BCC1084
CAS No.:137-58-6
- Calcium pantothenate
Catalog No.:BCN8503
CAS No.:137-08-6
- Sophoraflavanone I
Catalog No.:BCN6863
CAS No.:136997-69-8
- Sophoraflavanone H
Catalog No.:BCN6864
CAS No.:136997-68-7
- (-)-Syringaresnol-4-O-beta-D-apiofuranosyl-(1->2)-beta-D-glucopyranoside
Catalog No.:BCN1578
CAS No.:136997-64-3
- AHU-377 hemicalcium salt
Catalog No.:BCC5141
CAS No.:1369773-39-6
- PACAP 1-38
Catalog No.:BCC6962
CAS No.:137061-48-4
- Alprenolol hydrochloride
Catalog No.:BCC7490
CAS No.:13707-88-5
- Pimecrolimus
Catalog No.:BCC4703
CAS No.:137071-32-0
- Tolfenamic Acid
Catalog No.:BCC4438
CAS No.:13710-19-5
- (±)-Marmesin
Catalog No.:BCN3618
CAS No.:13710-70-8
- BETP
Catalog No.:BCC6286
CAS No.:1371569-69-5
- Toddalosin
Catalog No.:BCN6194
CAS No.:137182-37-7
- Spinorphin
Catalog No.:BCC2349
CAS No.:137201-62-8
- Sodium Orthovanadate
Catalog No.:BCC3856
CAS No.:13721-39-6
- Voriconazole
Catalog No.:BCC2275
CAS No.:137234-62-9
- Dodoviscin A
Catalog No.:BCN3927
CAS No.:1372527-25-7
- Dodoviscin H
Catalog No.:BCN3918
CAS No.:1372527-39-3
Walsuralactam A and preparation method and application to medicament thereof.
Walsuralactam A and preparation method and application to medicament thereof: CN 2011.
The invention provides novel Walsuralactam A (a compound in the formula I) with medical value and a method for extracting the compound from Walsura yunnanensis plants. Meanwhile, the invention also provides a medicinal composition and application of the compound and the medicinal composition thereof to preparation of a medicament for treating and preventing tumour, wherein the medicinal composition comprises the compound in the formula I, which is used as an active ingredient, and is used for treating and preventing the tumour.